Barclays launches U.S. biopharma coverage with four preferred picks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
February 24, 2026 10:11 AM ESTBofA Securities analyst Tim Anderson reiterated a Buy rating and $1,293.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Todays announcement that Novo Nordisk (covered by Sachin Jain) plans to slash GLP-1 list prices offers a flashy headline, but in our view the update is unlikely to have any material impact on the US market. The price announcement is relevant only to commercial insurance channel (est. 30% of 25... More
Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
February 24, 2026 7:41 AM ESTNovo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
"Under the changes, both Ozempic and Wegovy will list for $675 a month, effective Jan. 1, 2027. That is half of the current price tag for anti-obesity therapy Wegovy and a 34% cut for diabetes treatment Ozempic. The... More